Akers Biosciences Chlamydia Rapid Test Results Positive
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 8:33AM CDT
Shares of Akers Biosciences Inc. (AKER) surged 15.8% to close at $3.22 following the completion of a clinical trial on the company's Chlamydia rapid test.
BSX: 23.90 (+0.24), ICUI: 115.00 (+1.34), CAH: 80.38 (+0.94), AKER: 2.79 (+0.09)
Akers Biosciences Signs Distribution Agreement, Shares Rally
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 6:49AM CDT
Akers Biosciences Inc. (AKER) recently signed an agreement with Aero-Med, a division of Cardinal Health (CAH), to distribute its disposable breathalyzer.
BSX: 23.90 (+0.24), ICUI: 115.00 (+1.34), CAH: 80.38 (+0.94), AKER: 2.79 (+0.09)
Akers Biosciences Signs Distribution Agreement for BreathScan OxiChek(TM)
Marketwire Canada - Mon Jun 27, 6:00AM CDT
THOROFARE, NJ--(Marketwired - Jun 27, 2016) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR) (the "Company" or "Akers Bio"
AKER: 2.79 (+0.09), AKR: 36.66 (+0.70)
Akers Biosciences to Present at LD Micro Invitational Conference
Marketwire Canada - Fri Jun 03, 8:52AM CDT
THOROFARE, NJ--(Marketwired - Jun 3, 2016) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L) (the "Company"
AKER: 2.79 (+0.09)
Akers (AKER) Reports Q1 Earnings; Product Revenue Up 79.3%
Aparajita Dutta - Zacks Investment Research - Thu May 12, 7:46AM CDT
Akers' (AKER) first-quarter product revenue increased 79.3% from the year-ago quarter to $738,023
AKER: 2.79 (+0.09)
Akers Biosciences Reports Earnings for Q1 2016
Marketwire Canada - Thu May 12, 6:00AM CDT
PIFA Heparin/PF4 Rapid Tests Sales Up 88%; Total Revenues up 45%
AKER: 2.79 (+0.09), AKR: 36.66 (+0.70)
Akers Biosciences Announces Conference Call to Discuss Q1 2016 Earnings
Marketwired - Tue May 10, 6:00AM CDT
THOROFARE, NJ--(Marketwired - May 10, 2016) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"
AKER: 2.79 (+0.09)
Akers Biosciences (AKER) Q1 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Mon May 09, 7:52AM CDT
Akers Biosciences Inc (AKER) is expected to report first-quarter 2016 results on May 12.
CAPR: 4.02 (-0.07), STAA: 5.99 (+0.23), AKER: 2.79 (+0.09), VBLT: 4.38 (+0.09)
Akers Biosciences to Present at 'Pioneers 2016' Investor Conference
Marketwire Canada - Wed May 04, 1:00PM CDT
THOROFARE, NJ--(Marketwired - May 4, 2016) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR), (the "Company"
AKER: 2.79 (+0.09), AKR: 36.66 (+0.70)
Akers Board Rearrangement
Marketwired - Fri Apr 29, 6:01AM CDT
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"
AKER: 2.79 (+0.09)
Akers' Loss Widens in 2015, Revenues Deteriorate Y/Y
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 9:46AM CDT
Akers Biosciences Inc. (AKER) reported loss of $1.81 per share in full-year 2015, much wider than 66 cents recorded in 2014.
AMZN: 745.81 (+9.24), BAX: 46.65 (+0.53), AKER: 2.79 (+0.09), HRC: 51.37 (+0.57)
Akers Biosciences Reports Earnings for Fiscal Year 2015
Marketwired - Wed Mar 30, 6:00AM CDT
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L) ("Akers Bio" or the "Company"
AKER: 2.79 (+0.09)
What Awaits Akers Biosciences (AKER) in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 8:10AM CDT
Akers Biosciences Inc (AKER) is expected to report fourth-quarter 2015 earnings results on Mar 30.
AMZN: 745.81 (+9.24), AXDX: 16.78 (+0.10), AKER: 2.79 (+0.09)
Akers Biosciences' Protein Preparation Gets Patent Cover
Zacks Equity Research - Zacks Investment Research - Thu Mar 24, 9:10AM CDT
Akers Biosciences Inc. (AKER) recently won a patent from the United States Patent and Trademark Office (USPTO) for its proprietary protein preparation.
BAX: 46.65 (+0.53), LMAT: 13.70 (+0.14), AKER: 2.79 (+0.09), HRC: 51.37 (+0.57)
Akers Biosciences Allowed US Patent for Heparin/PF4 Antibody Detection
Marketwired - Wed Mar 23, 6:00AM CDT
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"
AKER: 2.79 (+0.09)